BIODELIVERY SCIENCES INTL (BDSI)
Common Stock
BIODELIVERY SCIENCES INTL
NASDAQ:BDSI (3/22/2022, 8:00:02 PM)
After market: 5.6 +0.01 (+0.18%)5.59
0 (-0.09%)
Company Profile
BioDelivery Sciences International, Inc. operates as a pharmaceutical company, which engages in the development and commercialization of new applications of approved therapeutics to address important unmet medical needs. The company is headquartered in Raleigh, North Carolina and currently employs 200 full-time employees. The company went IPO on 2002-06-25. The firm focuses on delivering therapies for individuals living with serious and debilitating chronic conditions. The Compnay builts a portfolio of products that includes utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA), drug-delivery technology to develop and commercialize new applications of therapies aimed at addressing important unmet medical needs. BEMA drug delivery technology consists of a small, bi-layered erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The firm's product candidates includes BELBUCA (buprenorphine buccal film), CIII, for Chronic Pain; Symproic (naldemedine), for Opioid Induced Constipation and ONSOLIS (fentanyl buccal soluble film) for Breakthrough Cancer Pain.
Company Info
BIODELIVERY SCIENCES INTL
4131 Parklake Ave Ste 225
Raleigh NORTH CAROLINA 27612
P: 19195829050.0
CEO: Jeffrey Bailey
Employees: 200
Website: https://www.bdsi.com/
BDSI News
2 years ago - Halper Sadeh LLPSHAREHOLDER NOTICE: Halper Sadeh LLP Investigates SJI, OBNK, CTXS, BDSI/PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
2 years ago - WeissLaw LLPSHAREHOLDER ALERT: WeissLaw LLP Reminds BDSI, MIME, VRS, and EPAY Shareholders About Its Ongoing Investigations/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...
The First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with or without Aura in Adults Expands BDSI Portfolio...
2 years ago - Halper Sadeh LLPSHAREHOLDER NOTICE: Halper Sadeh LLP Investigates FLOW, BDSI, CHWA, DNAA, CCMP/PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
2 years ago - Market News VideoInsiders Were Right: BDSI Makes New 52-Week High2 years ago - WeissLaw LLPSHAREHOLDER ALERT: WeissLaw LLP Reminds BDSI, FTSI, CCMP, and FLOW Shareholders About Its Ongoing Investigations/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...
BDSI Twits
Here you can normally see the latest stock twits on BDSI, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
